<p>隨着 ASX 200 指數徘徊在 9000 點以上，交易者在全球經濟事件和本地財報的背景下謹慎地應對市場。儘管存在一些猶豫，某些小型股票因其增長和價值潛力而繼續吸引投資者的關注。儘管 “便士股票” 這一術語較為陳舊，但它們仍然代表着在一些不太知名的公司中，具有強大基本面的投資機會，這些公司能夠提供穩定性和上漲潛力。</p>
<h3>澳大利亞十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$2.59</td>
<td>A$1.2218 億</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>GTN (ASX:GTN)</td>
<td>A$0.40</td>
<td>A$7627 萬</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$3.04</td>
<td>A$4.6871 億</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>SHAPE Australia (ASX:SHA)</td>
<td>A$4.31</td>
<td>A$3.5491 億</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>West African Resources (ASX:WAF)</td>
<td>A$2.79</td>
<td>A$31.8 億</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Regal Partners (ASX:RPL)</td>
<td>A$3.02</td>
<td>A$10.2 億</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Bravura Solutions (ASX:BVS)</td>
<td>A$2.28</td>
<td>A$10.2 億</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Austco Healthcare (ASX:AHC)</td>
<td>A$0.37</td>
<td>A$1.3523 億</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Austin Engineering (ASX:ANG)</td>
<td>A$0.315</td>
<td>A$1.9547 億</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>CTI Logistics (ASX:CLX)</td>
<td>A$1.855</td>
<td>A$1.4941 億</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們 ASX 便士股票篩選器中的 455 只股票的完整列表。</p>
<p>下面我們重點介紹幾隻我們獨家的篩選器中的最愛。</p>
<h2>AMA Group (ASX:AMA)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> AMA Group Limited 在澳大利亞和新西蘭運營碰撞修復業務，市值為 4.4956 億澳元。</p>
<p><strong>運營：</strong> 公司未報告具體的收入細分。</p>
<p><strong>市值：</strong> A$4.4956 億</p>
<p>AMA Group 的市值為 4.4956 億澳元，專注於澳大利亞和新西蘭的碰撞修復行業。儘管尚未盈利，但在過去五年中其虧損年均減少 21%，並保持了 7.2% 的淨負債與股本比率。該公司以顯著低於其估計公允價值的價格交易，分析師預計其價格有 22.3% 的上漲潛力。最近的財報顯示，截至 2025 年 6 月的年度銷售額增長至 10.1 億澳元，而淨虧損從 763 萬澳元略微改善至 747 萬澳元。</p>
<ul>
<li>在這裏深入瞭解 AMA Group 的具體情況，查看我們的全面資產負債表健康報告。</li>
<li>通過查看我們的增長報告，獲取 AMA Group 未來方向的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d903c2f6-0fdf-4047-a309-1525f5fdf3e3/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d903c2f6-0fdf-4047-a309-1525f5fdf3e3/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 8 月的 ASX:AMA 負債與股本歷史及分析</p>
<h2>Peet (ASX:PPC)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Peet Limited 在澳大利亞收購、開發和銷售住宅用地，市值為 8.0055 億澳元。</p>
<p><strong>運營：</strong> Peet 的收入主要來自公司自有項目（3.1324 億澳元），輔以基金管理（5639 萬澳元）和聯合安排（5188 萬澳元）。</p>
<p><strong>市值：</strong> A$8.0055 億</p>
<p>Peet Limited 的市值為 8.0055 億澳元，目前正在高盛的戰略審查下，旨在優化其資產基礎，以應對有利的市場條件。該公司報告了 2025 財年的強勁收益增長，銷售額達到 4.1479 億澳元，淨收入為 5847 萬澳元，反映出澳大利亞住宅物業市場的強勁需求。儘管負債水平較高（淨負債與股本比率為 45.8%），但 Peet 的債務得到了經營現金流的良好覆蓋，利息支付也由 EBIT 的 10.7 倍輕鬆管理。然而，管理團隊相對較新，平均任期為一年。</p>
<ul>
<li>在這裏閲讀我們的資產負債表健康報告，深入瞭解 Peet 的表現。</li>
<li>查看我們的歷史表現報告，以獲取 Peet 的業績記錄的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/993b423f-f3f9-4d37-9bcf-21b98c0b895b/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/993b423f-f3f9-4d37-9bcf-21b98c0b895b/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 8 月的 ASX:PPC 負債與股本歷史及分析</p>
<h2>XRF Scientific (ASX:XRF)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> XRF Scientific Limited 在澳大利亞、加拿大和歐洲製造和銷售貴金屬產品、專業化學品和儀器，市值為 3.1340 億澳元，服務於科學、分析、建築材料和礦業行業。</p>
<p><strong>運營：</strong> 公司的收入來自三個主要細分市場：消耗品（1926 萬澳元）、貴金屬（2151 萬澳元）和資本設備（2256 萬澳元）。</p>
<p><strong>市值：</strong> A$3.1340 億</p>
<p>XRF Scientific 的市值為 3.1340 億澳元，儘管銷售增長温和，但其財務韌性得到了體現。其 2025 財年的最新財報顯示，淨收入從前一年的 889 萬澳元上升至 1038 萬澳元，利潤率改善至 17.5%。公司的強大資產負債表表明，短期資產超過負債，且負債與股本比率在五年內從 14.5% 降至 4.4%，同時利息支付得到了良好覆蓋，經營現金流顯著超過債務水平。此外，XRF 經驗豐富的管理層和董事會增強了其在行業波動中的運營穩定性。</p>
<ul>
<li>在這裏深入瞭解 XRF Scientific 的全面分析健康報告。</li>
<li>瞭解 XRF Scientific 的未來增長軌跡。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9b63580b-4082-4ba3-bd48-ba43082e3621/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9b63580b-4082-4ba3-bd48-ba43082e3621/chart/financial-position-analysis"/></p>
<p>截至 2025 年 8 月的 ASX:XRF 財務狀況分析</p>
<h2>關鍵要點</h2>
<ul>
<li>在這裏查看我們完整的 455 只 ASX 便士股票目錄。</li>
<li>尋找其他投資？這 13 家公司在 COVID 之後生存並蓬勃發展，具備應對特朗普關税的正確要素。在您的投資組合感受到貿易戰壓力之前，瞭解原因。</li>
</ul>
<p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

<p>隨着 ASX 200 指數保持在 9000 點以上，交易者們開始關注具有增長潛力的低價股。值得注意的公司包括 AMA Group（ASX:AMA），該公司在碰撞修復領域運營，市值為 4.4956 億澳元，顯示出虧損減少和潛在的價格上漲。Peet Limited（ASX:PPC）正在進行戰略審查，住宅土地開發方面的收益強勁。XRF Scientific（ASX:XRF）展現出財務韌性，市值為 3.134 億澳元，利潤率有所改善。這些公司突顯了當前市場環境中的機會</p>

<p>As the ASX 200 hovers just above 9,000 points, traders are cautiously navigating the market amid global economic events and local earnings reports. Despite some hesitancy, certain smaller stocks continue to capture investor attention due to their potential for growth and value. Penny stocks, though an old term, still represent opportunities in lesser-known companies with strong fundamentals that can offer both stability and upside potential.</p>
<div class="lb-trans"><p>隨着 ASX 200 指數徘徊在 9000 點以上，交易者在全球經濟事件和本地財報的背景下謹慎地應對市場。儘管存在一些猶豫，某些小型股票因其增長和價值潛力而繼續吸引投資者的關注。儘管 “便士股票” 這一術語較為陳舊，但它們仍然代表着在一些不太知名的公司中，具有強大基本面的投資機會，這些公司能夠提供穩定性和上漲潛力。</p>
</div><h3>Top 10 Penny Stocks In Australia</h3>
<div class="lb-trans"><h3>澳大利亞十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$2.59</td>
<td>A$122.18M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>GTN (ASX:GTN)</td>
<td>A$0.40</td>
<td>A$76.27M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$3.04</td>
<td>A$468.71M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>SHAPE Australia (ASX:SHA)</td>
<td>A$4.31</td>
<td>A$354.91M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>West African Resources (ASX:WAF)</td>
<td>A$2.79</td>
<td>A$3.18B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Regal Partners (ASX:RPL)</td>
<td>A$3.02</td>
<td>A$1.02B</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Bravura Solutions (ASX:BVS)</td>
<td>A$2.28</td>
<td>A$1.02B</td>
<td>✅ 3 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Austco Healthcare (ASX:AHC)</td>
<td>A$0.37</td>
<td>A$135.23M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Austin Engineering (ASX:ANG)</td>
<td>A$0.315</td>
<td>A$195.47M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>CTI Logistics (ASX:CLX)</td>
<td>A$1.855</td>
<td>A$149.41M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$2.59</td>
<td>A$1.2218 億</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>GTN (ASX:GTN)</td>
<td>A$0.40</td>
<td>A$7627 萬</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$3.04</td>
<td>A$4.6871 億</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>SHAPE Australia (ASX:SHA)</td>
<td>A$4.31</td>
<td>A$3.5491 億</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>West African Resources (ASX:WAF)</td>
<td>A$2.79</td>
<td>A$31.8 億</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Regal Partners (ASX:RPL)</td>
<td>A$3.02</td>
<td>A$10.2 億</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Bravura Solutions (ASX:BVS)</td>
<td>A$2.28</td>
<td>A$10.2 億</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Austco Healthcare (ASX:AHC)</td>
<td>A$0.37</td>
<td>A$1.3523 億</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Austin Engineering (ASX:ANG)</td>
<td>A$0.315</td>
<td>A$1.9547 億</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>CTI Logistics (ASX:CLX)</td>
<td>A$1.855</td>
<td>A$1.4941 億</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 455 stocks from our ASX Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們 ASX 便士股票篩選器中的 455 只股票的完整列表。</p>
</div><p>Below we spotlight a couple of our favorites from our exclusive screener.</p>
<div class="lb-trans"><p>下面我們重點介紹幾隻我們獨家的篩選器中的最愛。</p>
</div><h2>AMA Group (ASX:AMA)</h2>
<div class="lb-trans"><h2>AMA Group (ASX:AMA)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> AMA Group Limited operates a collision repair business across Australia and New Zealand, with a market cap of A$449.56 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> AMA Group Limited 在澳大利亞和新西蘭運營碰撞修復業務，市值為 4.4956 億澳元。</p>
</div><p><strong>Operations:</strong> No specific revenue segments are reported for the company.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司未報告具體的收入細分。</p>
</div><p><strong>Market Cap:</strong> A$449.56M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$4.4956 億</p>
</div><p>AMA Group, with a market cap of A$449.56 million, operates in the collision repair sector across Australia and New Zealand. Despite being unprofitable, it has reduced losses by 21% annually over the past five years and maintains a satisfactory net debt to equity ratio of 7.2%. The company trades at a significant discount to its estimated fair value and analysts anticipate a potential price increase of 22.3%. Recent earnings show sales growth to A$1.01 billion for the year ended June 2025, while net loss slightly improved from A$7.63 million to A$7.47 million year-on-year.</p>
<div class="lb-trans"><p>AMA Group 的市值為 4.4956 億澳元，專注於澳大利亞和新西蘭的碰撞修復行業。儘管尚未盈利，但在過去五年中其虧損年均減少 21%，並保持了 7.2% 的淨負債與股本比率。該公司以顯著低於其估計公允價值的價格交易，分析師預計其價格有 22.3% 的上漲潛力。最近的財報顯示，截至 2025 年 6 月的年度銷售額增長至 10.1 億澳元，而淨虧損從 763 萬澳元略微改善至 747 萬澳元。</p>
</div><ul>
<li>Dive into the specifics of AMA Group here with our thorough balance sheet health report.</li>
<li>Gain insights into AMA Group's future direction by reviewing our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏深入瞭解 AMA Group 的具體情況，查看我們的全面資產負債表健康報告。</li>
<li>通過查看我們的增長報告，獲取 AMA Group 未來方向的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d903c2f6-0fdf-4047-a309-1525f5fdf3e3/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/d903c2f6-0fdf-4047-a309-1525f5fdf3e3/chart/debt-equity-history-analysis"/></p>
<p>ASX:AMA Debt to Equity History and Analysis as at Aug 2025</p>
<div class="lb-trans"><p>截至 2025 年 8 月的 ASX:AMA 負債與股本歷史及分析</p>
</div><h2>Peet (ASX:PPC)</h2>
<div class="lb-trans"><h2>Peet (ASX:PPC)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Peet Limited acquires, develops, and markets residential land in Australia with a market cap of A$800.55 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Peet Limited 在澳大利亞收購、開發和銷售住宅用地，市值為 8.0055 億澳元。</p>
</div><p><strong>Operations:</strong> Peet's revenue is primarily derived from Company Owned Projects (A$313.24 million), complemented by Funds Management (A$56.39 million) and Joint Arrangements (A$51.88 million).</p>
<div class="lb-trans"><p><strong>運營：</strong> Peet 的收入主要來自公司自有項目（3.1324 億澳元），輔以基金管理（5639 萬澳元）和聯合安排（5188 萬澳元）。</p>
</div><p><strong>Market Cap:</strong> A$800.55M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$8.0055 億</p>
</div><p>Peet Limited, with a market cap of A$800.55 million, is navigating a strategic review led by Goldman Sachs to optimize its asset base amidst favorable market conditions. The company reported robust earnings growth for FY25, with sales reaching A$414.79 million and net income at A$58.47 million, reflecting strong demand in the Australian residential property sector. Despite high debt levels (net debt to equity ratio of 45.8%), Peet's debt is well-covered by operating cash flow and interest payments are comfortably managed by EBIT coverage of 10.7x. However, the management team is relatively new with an average tenure of one year.</p>
<div class="lb-trans"><p>Peet Limited 的市值為 8.0055 億澳元，目前正在高盛的戰略審查下，旨在優化其資產基礎，以應對有利的市場條件。該公司報告了 2025 財年的強勁收益增長，銷售額達到 4.1479 億澳元，淨收入為 5847 萬澳元，反映出澳大利亞住宅物業市場的強勁需求。儘管負債水平較高（淨負債與股本比率為 45.8%），但 Peet 的債務得到了經營現金流的良好覆蓋，利息支付也由 EBIT 的 10.7 倍輕鬆管理。然而，管理團隊相對較新，平均任期為一年。</p>
</div><ul>
<li>Get an in-depth perspective on Peet's performance by reading our balance sheet health report here.</li>
<li>Review our historical performance report to gain insights into Peet's track record.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏閲讀我們的資產負債表健康報告，深入瞭解 Peet 的表現。</li>
<li>查看我們的歷史表現報告，以獲取 Peet 的業績記錄的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/993b423f-f3f9-4d37-9bcf-21b98c0b895b/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/993b423f-f3f9-4d37-9bcf-21b98c0b895b/chart/debt-equity-history-analysis"/></p>
<p>ASX:PPC Debt to Equity History and Analysis as at Aug 2025</p>
<div class="lb-trans"><p>截至 2025 年 8 月的 ASX:PPC 負債與股本歷史及分析</p>
</div><h2>XRF Scientific (ASX:XRF)</h2>
<div class="lb-trans"><h2>XRF Scientific (ASX:XRF)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> XRF Scientific Limited manufactures and markets precious metal products, specialized chemicals, and instruments for the scientific, analytical, construction material, and mining industries across Australia, Canada, and Europe with a market cap of A$313.40 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> XRF Scientific Limited 在澳大利亞、加拿大和歐洲製造和銷售貴金屬產品、專業化學品和儀器，市值為 3.1340 億澳元，服務於科學、分析、建築材料和礦業行業。</p>
</div><p><strong>Operations:</strong> The company's revenue is derived from three main segments: Consumables (A$19.26 million), Precious Metals (A$21.51 million), and Capital Equipment (A$22.56 million).</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入來自三個主要細分市場：消耗品（1926 萬澳元）、貴金屬（2151 萬澳元）和資本設備（2256 萬澳元）。</p>
</div><p><strong>Market Cap:</strong> A$313.4M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$3.1340 億</p>
</div><p>XRF Scientific, with a market cap of A$313.40 million, has demonstrated financial resilience despite modest sales growth. Its recent earnings report for FY25 shows net income rising to A$10.38 million from A$8.89 million the previous year, highlighting improved profit margins at 17.5%. The company's strong balance sheet is evidenced by short-term assets exceeding liabilities and a reduced debt-to-equity ratio from 14.5% to 4.4% over five years, complemented by well-covered interest payments and operating cash flow surpassing debt levels significantly. Furthermore, XRF's seasoned management and board enhance its operational stability amidst industry volatility.</p>
<div class="lb-trans"><p>XRF Scientific 的市值為 3.1340 億澳元，儘管銷售增長温和，但其財務韌性得到了體現。其 2025 財年的最新財報顯示，淨收入從前一年的 889 萬澳元上升至 1038 萬澳元，利潤率改善至 17.5%。公司的強大資產負債表表明，短期資產超過負債，且負債與股本比率在五年內從 14.5% 降至 4.4%，同時利息支付得到了良好覆蓋，經營現金流顯著超過債務水平。此外，XRF 經驗豐富的管理層和董事會增強了其在行業波動中的運營穩定性。</p>
</div><ul>
<li>Jump into the full analysis health report here for a deeper understanding of XRF Scientific.</li>
<li>Learn about XRF Scientific's future growth trajectory here.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏深入瞭解 XRF Scientific 的全面分析健康報告。</li>
<li>瞭解 XRF Scientific 的未來增長軌跡。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9b63580b-4082-4ba3-bd48-ba43082e3621/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/9b63580b-4082-4ba3-bd48-ba43082e3621/chart/financial-position-analysis"/></p>
<p>ASX:XRF Financial Position Analysis as at Aug 2025</p>
<div class="lb-trans"><p>截至 2025 年 8 月的 ASX:XRF 財務狀況分析</p>
</div><h2>Key Takeaways</h2>
<div class="lb-trans"><h2>關鍵要點</h2>
</div><ul>
<li>Jump into our full catalog of 455 ASX Penny Stocks here.</li>
<li>Seeking Other Investments? These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏查看我們完整的 455 只 ASX 便士股票目錄。</li>
<li>尋找其他投資？這 13 家公司在 COVID 之後生存並蓬勃發展，具備應對特朗普關税的正確要素。在您的投資組合感受到貿易戰壓力之前，瞭解原因。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

AMA 集團及其他兩個澳大利亞證券交易所的便士股票值得關注